eli lilly retatrutide - Stock Newsroom

S TOCK newsroom .COM

S&P 500 6,833 +0.73%

DJIA 48,280 +0.77%

Nasdaq 25,073 +0.72%

DAX 23,901 -0.26%

Gold $4,196 +0.16%

Oil $98.10 +1.46%

BTC $72,062 +0.97%

VIX 20.48 -15.65%

EUR/USD 1.1785 -0.02%

ETH $2,217 +0.37%

S&P 500 6,833 +0.73%

DJIA 48,280 +0.77%

Nasdaq 25,073 +0.72%

DAX 23,901 -0.26%

Gold $4,196 +0.16%

Oil $98.10 +1.46%

BTC $72,062 +0.97%

VIX 20.48 -15.65%

EUR/USD 1.1785 -0.02%

ETH $2,217 +0.37%

eli lilly retatrutide

Eli Lilly Retatrutide injection pen symbolizing triple-agonist diabetes and obesity treatment boom

Pharma & Healthcare·Stocks·USA

Eli Lilly Retatrutide Boom: Triple-Agonist Trial Shock

By Maik Kemper • Mar 19, 2026

Eli Lilly Retatrutide injection pen symbolizing triple-agonist diabetes and obesity treatment boom

Pharma & Healthcare·Stocks·USA

Eli Lilly Retatrutide Boom: Triple-Agonist Trial Shock

By Maik Kemper • Mar 19, 2026

Can Eli Lilly Retatrutide’s powerful Phase 3 diabetes data reignite confidence in the GLP-1 boom despite rising competitive and pricing fears? Maik Kemper Editor in…